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EDITORIAL ON "OCCULT CERVICAL NODAL METASTASES IN ESOPHAGEAL CANCER: 
PRELIMINARY RESULTS OF THREE-FIELD LYMPHADENECTOMY" 
Mark B. Orringer, MD 
I n the following report, Altorki and Skinner have documented the presence of unsuspected cervical 
lymph node metastases in one third (10/30) of their 
patients undergoing radical en bloc esophagectomy for 
presumably "curable" carcinoma of the thoracic 
esophagus. Cervical ymph node metastases occurred 
in four (26%) of the 15 patients with adenocarcinoma 
and in six (40%) of the 15 with squamous cell carci- 
noma. Cervical ymph nodes were involved in these 
patients just as often as mediastinal nodes and irre- 
spective of the tumor site or depth of penetration of
the esophageal wall. Even in patients with metastasis 
to only one lymph node, traditionally regarded as a 
good prognostic sign, the cervical region was as likely 
to be involved as the mediastinal orperigastric regions. 
This series is small, but the data are sobering and 
certainly fuel the current flames of controversy sur- 
rounding the optimal therapy for esophageal cancer. 
Historically, Japanese surgeons have carried the 
mantra of extended lymphadenectomy in the treat- 
ment of esophageal carcinoma, claiming that resection 
of lymph nodes in these patients is therapeutic. The 
majority of Western esophageal surgeons, on the other 
hand, have for the most part removed readily accessi- 
ble regional lymph nodes at the time of esophagec- 
tomy for the purpose of staging rather than with any 
expectation of improving survival. A number of Japa- 
nese surgeons, a few European surgeons, and now 
Altorki and Skinner have reported cervical lymph 
node metastases to be present in 20% to 30% of 
patients undergoing three-field ymphadenectomy (the 
traditional mediastinal nd upper abdominal lymph 
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node dissections but now with the addition of cervical 
lymph node dissection). Recent reports from Japan on 
three-field lymphadenectomy have suggested survival 
benefit from such an aggressive surgical approach. 
The majority of Western surgeons, however, and I 
am one of them, have difficulty "swallowing" the 
radical surgical approach to esophageal carcinoma. 
Few of us have been able to duplicate the reported 
survival statistics of patients undergoing esophagec- 
tomy for carcinoma in Japan, and a possible biologic 
difference in these tumors in our respective countries 
has been suggested as one explanation. The vast 
majority of patients with esophageal carcinoma whom 
we treat are surgically incurable by virtue of distant 
metastatic disease or local tumor invasion when they 
first arrive for treatment. To approach a tumor, which 
for the most part is already systemic, with a local 
treatment modality such as surgery with any reason- 
able expectation of achieving long-term survival or 
cure is a noble but unrealistic undertaking. To justify 
the potential added morbidity of an extensive medias- 
tinal and now cervical dissection in these patients 
stretches the limits of the imagination. 
It is a curious human characteristic that like the 
three blind men feeling different parts of the ele- 
phant, each of us interprets data presented to us in 
the framework of our own reference system. For 
Altorki and Skinner, the finding of unsuspected 
cervical ymph node metastases translates to a need 
to be more aggressive in resecting lymph nodes at 
the time of radical esophagectomy for carcinoma. 
For me, the data presented in this report only 
further einforce my conviction that systemic disease 
in these patients is seldom cured with a scalpel 
alone. Consequently, I continue to champion a 
transhiatal esophagectomy and cervical esophago- 
gastrostomy whenever possible in patients with 
esophageal carcinoma. The University of Michigan 
Thoracic Surgery Service has performed more than 
1000 of these operations, and the technique has 
been refined to the point that operative time aver- 
ages 4 hours, mortality is in the range of 1%, no 
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blood transfusions are given, no postoperative inten- 
sive care is required, and hospitalization is 7 to 10 
days. As technical modifications have lowered the 
cervical anastomotic leak rate to below 5%, no other 
therapy currently available for the treatment of 
esophageal carcinoma can restore comfortable swal- 
lowing as elficiently. 
Compelling questions about he wisdom of radical 
esophagectomy and three-field lymphadenectomy 
need to be answered before this approach can be 
accepted more widely. Are survival rates with such 
an extensive operation actually improved enough to 
justify the potential increased moicbidity? Stripping 
tracheobronchial nd mediastinal lymphatics may 
result in reflex bronchorrhea nd the need for 
prolonged postoperative mechanical ventilation. 
Dissection of lymph nodes around the recurrent 
laryngeal nerves may produce not only hoarseness if 
the nerve is injured but also life-threatening aspira- 
tion owing to impaired swallowing from resulting 
neuromotor dysfunction of the upper esophageal 
sphincter. Does approaching the left recurrent la- 
ryngeal nerve lymph nodes from the right side of the 
chest provide adequate xposure, or should a partial 
sternal split be performed to facilitate the removal 
of high left paraesophageal lymph nodes? And 
inevitable questions relevant to the current man- 
aged care environment arise from this report as well. 
Are two teams of surgeons required for the simul- 
taneous cervical and abdominal phases of the oper- 
ation (that translates into increased physician charg- 
es)? By how much time is the operation increased by 
the cervical node dissection (increased use of oper- 
ating room resources)? Don't the longer operative 
and anesthetic times, more extensive dissection, 
increased postoperative bronchorrhea, nd the need 
for more mechanical ventilation in the intensive care 
setting translate to greater cost? 
The proponents of radical esophagectomy for 
esophageal carcinoma must explain why mediastinal 
lymph node metastases, and certainly extrathoracic 
nodal spread (e.g., to supraclavicular lymph nodes), 
are almost uniformly regarded as an indicator of 
incurability and therefore inoperability for the other 
major chest malignancy--lung cancer--but not for 
esophageal carcinoma. And where does the lymph 
node "chase" end? If the preoperative computed 
tomographic scan reveals retroperitoneal paraaortic 
lymph node adenopathy that is confirmed as being 
due to metastatic disease with a fine needle aspira- 
tion, should the patient be deemed unsuitable for 
surgical treatment by virtue of having stage IV 
disease, or should a retroperitoneal lymph node 
dissection be added to the operation? The data 
presented by Altorki and Skinner are indeed sober- 
ing. If cervical nodal metastases are regarded as 
indicative as extrathoracic disease, patients with 
such metastases have stage IV tumors, which are 
typically associated with a survival of 6 months. If 
one third of all patients with esophageal carcinoma 
have cervical lymph node metastases, should routine 
cervical ymph node dissection become a standard 
part of the preoperative evaluation (reminiscent of 
scalene node biopsy for lung cancer) and those 
patients with metastases be excluded from opera- 
tion? Prospective well-controlled trials are needed 
to answer the many questions timulated by this 
provocative report. 
